U.S. markets closed

  • S&P Futures

    4,329.25
    -8.25 (-0.19%)
     

  • Dow Futures

    33,863.00
    -29.00 (-0.09%)
     

  • Nasdaq Futures

    14,836.25
    -23.50 (-0.16%)
     

  • Russell 2000 Futures

    1,805.80
    -3.30 (-0.18%)
     

  • Crude Oil

    91.68
    -0.03 (-0.03%)
     

  • Gold

    1,882.20
    +3.60 (+0.19%)
     

  • Silver

    22.84
    +0.10 (+0.44%)
     

  • EUR/USD

    1.0573
    +0.0006 (+0.05%)
     

  • 10-Yr Bond

    4.5970
    -0.0290 (-0.63%)
     

  • Vix

    17.34
    -0.88 (-4.83%)
     

  • GBP/USD

    1.2208
    +0.0002 (+0.02%)
     

  • USD/JPY

    149.3400
    +0.0660 (+0.04%)
     

  • Bitcoin USD

    27,011.54
    +576.54 (+2.18%)
     

  • CMC Crypto 200

    579.54
    +14.75 (+2.61%)
     

  • FTSE 100

    7,601.85
    +8.63 (+0.11%)
     

  • Nikkei 225

    31,823.96
    -48.56 (-0.15%)
     

U.S. Supreme Court to hear Amgen bid to revive Repatha patents

Reuters
·1 min read

WASHINGTON, Nov 4 (Reuters) - The U.S. Supreme Court on Friday agreed to hear Amgen Inc's bid to revive patents on its cholesterol drug Repatha that were invalidated due to a legal challenge by rivals Regeneron Pharmaceuticals Inc and Sanofi SA.

The justices took up Amgen's appeal of the lower court ruling that threw out the Repatha patents. Amgen and other drugmakers have called the case a test of their ability to earn and defend patents for important drugs. Amgen first sued Regeneron and Sanofi in 2014 over their rival drug Praluent. (Reporting by Blake Brittain in Washington and Nate Raymond in Boston; editing by Jonathan Oatis)